journal
MENU ▼
Read by QxMD icon Read
search

Asia-Pacific Journal of Clinical Oncology

journal
https://www.readbyqxmd.com/read/28699304/immune-checkpoint-inhibitors-navigating-a-new-paradigm-of-treatment-toxicities
#1
REVIEW
Kate Roberts, Vanessa Culleton, Zarnie Lwin, Kenneth O'Byrne, Brett Gm Hughes
Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a broad spectrum of malignancies. This new class of agents also challenges oncologists with a unique set of immune-based toxicities. Early recognition and precise management of these toxicities can result in better outcomes, with minimization of toxicity and harm to the patient. This article provides a comprehensive review of immune-based toxicities caused by immune checkpoint inhibitors, including recommendations for their investigation and guidelines for specific management...
July 12, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28699260/australian-recommendations-for-egfr-t790m-testing-in-advanced-non-small-cell-lung-cancer
#2
REVIEW
Thomas John, Jeffrey J Bowden, Stephen Clarke, Stephen B Fox, Kerryn Garrett, Keith Horwood, Christos S Karapetis
First-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring a sensitizing mutation in the EGFR gene. Unfortunately, resistance to these therapies often occurs within 10 months of commencing treatment and is mostly commonly due to the development of the EGFR T790M mutation. Treatment with the third-generation EGFR TKI, osimertinib can prolong progression free survival in patients with the T790M mutation, so it is important to determine the resistance mechanism in order to plan ongoing therapeutic strategies...
July 12, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28695689/patterns-of-health-services-utilization-in-the-last-two-weeks-of-life-among-cancer-patients-experience-in-an-australian-academic-cancer-center
#3
Wee Loon Ong, Richard Khor, Mathias Bressel, Phillip Tran, Jo Tedesco, Keen Hun Tai, David Ball, Gillian Duchesne, Farshad Foroudi
AIM: To report the trend in end-of-life health services (HS) utilization among cancer patients treated in a large Australian academic cancer center over a 12-year period. METHODS: This is a retrospective study of cancer patients treated at the Peter MacCallum Cancer Centre (PMCC), who had documented death between January 2002 and December 2013. Using administrative and billing database, we report on the utilization of different categories of HS within two weeks of death: diagnostic investigations (pathology and radiology), inpatient and outpatient services, and potentially futile interventions (PFI, which include radiotherapy, chemotherapy and surgery)...
July 11, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28695683/combinations-of-single-nucleotide-polymorphisms-wwox-rs13338697-galnt14-rs9679162-and-rs6025211-effectively-stratify-outcomes-of-chemotherapy-in-advanced-hepatocellular-carcinoma
#4
Wey-Ran Lin, Chao-Wei Hsu, Christopher Sung-Huan Yeh, Yi-Cheng Chen, Ming-Ling Chang, Kung-Hao Liang, Chen-Chun Lin, Yu-De Chu, Chau-Ting Yeh
AIM: A genome-wide association study (GWAS) had identified a single nucleotide polymorphism (SNP), GALNT14-rs9679162, capable of predicting chemotherapy responses in advanced hepatocellular carcinoma (HCC). Here, we revisited the GWAS database to search for necessary SNPs that could improve our outcome prediction. METHODS: A cohort of 116 HCC patients receiving split-dose chemotherapy composed of 5-fluorouracil, mitoxantrone and cisplatin was enrolled. The GALNT14-rs9679162 together with four other leading candidate SNPs (rs6025211, rs715171, LOC105369482-rs1955024 and WWOX-rs13338697) was genotyped and correlated with time-to-tumor progression (TTP) and overall survival (OS)...
July 11, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28695617/morbidity-and-mortality-of-elderly-patients-following-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec
#5
Evelyn Y T Wong, Grace H C Tan, Claramae S L Chia, Mrinal Kumar, Khee Chee Soo, Melissa C C Teo
AIM: Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is known to improve survival in selected patients with peritoneal metastasis. However, there is limited data supporting the role of CRS and HIPEC in elderly patients (≥65 years old). METHODS: A retrospective review of a prospectively maintained database of patients who underwent CRS-HIPEC between April 2001 and July 2015 from a single institution was performed. Patients were divided into two groups non-elderly (<65 years old), and elderly (≥65 years old)...
July 11, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28670820/inadequate-treatment-practices-for-pain-relief-and-adverse-event-management-in-cancer-patients-across-10-countries-regions-in-asia-a-call-for-greater-efforts-to-improve-standards-for-patient-care
#6
Kok Yuen Ho, Jin Seok Ahn, Maria Minerva Calimag, Ta-Chung Chao, Yong-Chul Kim, Hanlim Moon, Lye Mun Tho, Zhong-Jun Xia, Dora You
AIM: To examine the treatment practices for cancer pain relief and adverse event management, and the factors related to patient outcomes in the participating countries/regions. METHODS: The study was a cross-sectional survey conducted between September and December 2013 in 10 countries/regions across Asia. Adult patients with a history of cancer pain at least 1 month before study entry completed the survey questionnaire. RESULTS: A total of 1190 patients were included...
July 3, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28670761/models-of-childhood-cancer-survivorship-care-in-australia-and-new-zealand-strengths-and-challenges
#7
Christina Signorelli, Claire E Wakefield, Jordana K McLoone, Joanna E Fardell, Renae A Lawrence, Michael Osborn, Jo Truscott, Heather Tapp, Richard J Cohn
AIM: Childhood cancer survivors remain at risk of developing life-altering and/or life-threatening health conditions following the completion of curative treatment. However, no uniform model of care for childhood cancer survivors exists in Australia and New Zealand (ANZ). This study reports on current childhood cancer survivorship care in ANZ, highlighting the challenges childhood cancer survivor long-term follow-up (LTFU) clinics face. METHODS: We conducted semistructured, telephone interviews with the pediatric medical director and clinical nurse consultant from all 11 LTFU clinics at tertiary referral pediatric oncology units across ANZ (n = 19; 100% response rate)...
July 3, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28670694/medical-and-non-medical-expenditure-for-breast-cancer-diagnosis-and-treatment-in-china-a-multicenter-cross-sectional-study
#8
Xian-Zhen Liao, Ju-Fang Shi, Jing-Shi Liu, Hui-Yao Huang, Lan-Wei Guo, Xin-Yu Zhu, Hai-Fan Xiao, Le Wang, Ya-Na Bai, Guo-Xiang Liu, A-Yan Mao, Jian-Song Ren, Xiao-Jie Sun, Ling Mai, Yu-Qin Liu, Bing-Bing Song, Ji-Yong Gong, Jin-Yi Zhou, Ling-Bing Du, Qi Zhou, Rong Cao, Lin Zhu, Ying Ren, Pei-An Lou, Li Lan, Xiao-Hua Sun, Xiao Qi, Yuan-Zheng Wang, Kai Zhang, Jie He, Min Dai
AIM: We aimed to assess economic burden of breast cancer (BC) diagnosis and treatment in China through a multicenter cross-sectional study, and to obtain theoretical evidence for policy-making. METHODS: This survey was conducted in 37 hospital centers across 13 provinces in China from September 2012 to December 2014. We collected information on the subject characteristics. We then assessed the medical and non-medical expenditure for BC diagnosis and treatment, factors influencing the average case expense, variations between medical and non-medical expenditure at different clinical stages, economic impact of overall expenditure in newly diagnosed course after reimbursement to the patient's family, composition of non-medical expenditure and time loss for the patient and family...
July 3, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28661584/clinical-and-palliative-care-outcomes-for-patients-of-poor-performance-status-treated-with-antiprogrammed-death-1-monoclonal-antibodies-for-advanced-melanoma
#9
Annie Wong, Molly Williams, Donna Milne, Kortnye Morris, Peter Lau, Odette Spruyt, Sonia Fullerton, Grant McArthur
BACKGROUND: Antiprogrammed death-1 antibodies (anti-PD1) have response rates of 40% in metastatic melanoma. Patients with poor performance status (PS) were excluded from clinical trials, yet use of anti-PD1 is widespread in clinical practice. Literature regarding clinical and palliative care outcomes in patients with poor PS treated with anti-PD1 is lacking. METHODS: Retrospective review of outcomes for all patients with advanced melanoma treated with anti-PD1 between 2012 and June 2015 at Peter MacCallum Cancer Centre, a tertiary specialist cancer center in Australia...
June 29, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28653815/factors-associated-with-the-development-and-severity-of-oxaliplatin-induced-peripheral-neuropathy-a-systematic-review
#10
REVIEW
Jeremy N Pulvers, Gavin Marx
Oxaliplatin is a platinum-derivative chemotherapeutic agent used for colorectal cancer in the adjuvant and metastatic setting in combination with folinic acid and 5-fluorouracil. Oxaliplatin causes an acute cold-induced neurotoxicity and a chronic cumulative neuropathy, which can require dose modification and impact quality of life. To date, no prevention and treatment strategies have proved effective thus reinforcing the importance of identifying at-risk patients in order to maximize therapeutic benefit while minimizing neurotoxicity...
June 27, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28589647/using-primary-tumor-volumetry-to-predict-treatment-outcome-for-patients-with-oropharyngeal-cancer-who-were-treated-with-definitive-chemoradiotherapy
#11
Yun Hee Lee, Jin Ho Song, Hoon-Sik Choi, Hojin Jeong, Ki Mun Kang, Jung Hun Kang, Seung Hoon Woo, Jung Je Park, Jin Pyeong Kim, Bae Kwon Jeong
AIM: This study aimed to determine predictive values for volumetric measures in patients with oropharyngeal cancer who received definitive chemoradiotherapy (CCRT). METHODS: Contrast-enhanced computed tomography (CT) scans were obtained before radiotherapy (RT) (I), after delivering a median RT of 50.6 Gy (R) and three months after RT (F). Primary site gross tumor volumes (GTV) were assessed using these scans (GTVI , GTVR and GTVF ). The percentage volume change between GTVI and GTVR (GTV change) was calculated...
June 7, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28547805/quality-and-impact-of-eviq-cancer-treatments-online-www-eviq-org-au-the-medical-oncologist-s-perspective
#12
Lydia P Y Loke, Tina Y T Chen, Craig R Lewis, Robyn L Ward, Shelley A Rushton, Jeremy D Shapiro
INTRODUCTION: eviQ Cancer Treatments Online is a free, web-based resource providing access to over 600 evidence-based treatment protocols in medical oncology, radiation oncology, hematology and cancer genetics. With over 60 000 registrants from 148 countries, eviQ is widely used by cancer clinicians globally. The aim of this study was to examine the perceived quality of eviQ by Australian medical oncologists, the impact it had on their knowledge and practice, and the effect it had on their patients...
May 25, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28544809/robotic-radiosurgery-of-head-and-neck-paragangliomas-a-single-institution-experience
#13
İlker Tosun, Banu Atalar, Bilgehan Şahin, Görkem Güngör, Gökhan Aydin, Bülent Yapici, Enis Özyar
AIM: CyberKnife(®) is a robotic stereotactic radiotherapy system. The aim of this study is to evaluate the effectiveness and the safety of CyberKnife(®) on treating head and neck paragangliomas and to report our results. METHODS: Between March 2009 and June 2014, 12 patients with head and neck paragangliomas have been referred to our clinic: in three cases had jugular paragangliomas, five cases had carotid body paragangliomas and three cases had tympanic paragangliomas...
May 24, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28544358/the-expression-pattern-of-bcl11a-mdm2-and-pten-genes-in-b-cell-acute-lymphoblastic-leukemia
#14
Ling Xu, Hong Wu, Xiuli Wu, Yangqiu Li, Dongmei He
AIM: Bcl11a is closely associated with B-cell lymphoma and B-cell chronic lymphocytic leukemia. However, little is known about the expression character of Bcl11a gene in B-cell acute lymphoblastic leukemia (B-ALL). In previous study, our results showed there was a clear dysregulation in the global gene expression of the Bcl11a-suppressed B lymphoma cells. The aim of the study is to further evaluate the role of Bcl11a and the expression level of its related genes Mdm2, Pten in B-ALL patients...
May 24, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28488392/risk-factors-for-locoregional-relapse-after-radical-nephrectomy
#15
Sameer Jhavar, Gregory Swanson, Jessica Pruszynski
AIM: To identify risk factors for locoregional relapse after radical nephrectomy for renal cell carcinoma. METHODS: We retrospectively reviewed the charts of 259 patients who underwent radical nephrectomy for sporadic clinically localized unilateral renal cell carcinoma between 1998 and 2012. Relapse patterns (locoregional and/or distant) were identified. Relapse-free survival was calculated using Kaplan-Meier method. Factors associated with decreased relapse-free survival were identified using univariate and multivariate Cox proportional hazards regression model analysis...
May 10, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28488380/addition-of-oxaliplatin-to-neoadjuvant-radiochemotherapy-in-mri-defined-t3-t4-or-n-rectal-cancer-a-randomized-clinical-trial
#16
Peiman Haddad, Monir Miraie, Farshid Farhan, Mohammad-Sadegh Fazeli, Afsaneh Alikhassi, Afsaneh Maddah-Safaei, Mahdi Aghili, Bita Kalaghchi, Mohammad Babaei
BACKGROUND: Clinical trials investigating the effects of addition of oxaliplatin to neoadjuvant radiochemotherapy in locally advanced rectal cancers (LARCs) have brought controversial results for pathologic complete response as an endpoint. This randomized clinical trial investigated downstaging as a short-term surrogate for progression-free survival (PFS). METHODS: Patients with magnetic resonance imaging (MRI) defined T3, T4 or N+ histologically proven adenocarcinoma of rectum within 15 cm from anal verge were randomly assigned to receive 50-50...
May 10, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28488360/cabazitaxel-in-patients-with-metastatic-castration-resistant-prostate-cancer-safety-and-quality-of-life-data-from-the-australian-early-access-program
#17
Phillip Parente, Siobhan Ng, Francis Parnis, Alex Guminski, Howard Gurney
AIM: Cabazitaxel is a next generation taxane that has been shown to improve overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed during or after docetaxel-based therapy. A worldwide early access program (EAP) study was established to provide access to cabazitaxel ahead of commercial availability and to evaluate its safety and tolerability. The Australian EAP included patient-reported outcomes to evaluate the impact of cabazitaxel on quality of life (QoL)...
May 10, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28464497/utilization-pattern-and-survival-outcomes-of-adjuvant-therapies-in-high-grade-nonretroperitoneal-abdominal-soft-tissue-sarcoma-a-population-based-study
#18
William Ross Green, Ravi Chokshi, Salma K Jabbour, Thomas F DeLaney, Omar Mahmoud
BACKGROUND: Nonretroperitoneal abdominal soft tissue sarcoma (NRA-STS) is a rare disease with limited data supporting its management. Our study aimed to reveal the utilization patterns of adjuvant therapy and its potential survival benefits using the National Cancer Data Base. MATERIALS: The analysis included patients with resected high-grade NRA-STS. Chi-square analysis was used to evaluate distribution of patient and tumor-related factors within treatment groups...
May 2, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28464435/management-of-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-related-cutaneous-and-gastrointestinal-toxicities
#19
REVIEW
Derrick Chen-Wee Aw, Eng Huat Tan, Tan Min Chin, Hong Liang Lim, Haur Yueh Lee, Ross A Soo
Patients with advanced stage non-small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations using EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib and afatinib as first-line treatment had better progression-free survival, overall response rate and quality of life than those on chemotherapy. Although EGFR TKIs are commonly associated with skin-related (rash, xerosis and paronychia) and gastrointestinal-related (diarrhea and stomatitis) adverse events (AEs), these effects are usually mild...
May 2, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28719131/international-speakers
#20
(no author information available yet)
No abstract text is available yet for this article.
August 2017: Asia-Pacific Journal of Clinical Oncology
journal
journal
40999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"